Association between Body Mass Index and Survival Outcome in Metastatic Cancer Patients Treated by Immunotherapy: Analysis of a French Retrospective Cohort.
advanced cancer
body mass index
immune-related adverse events
immunotherapy
survival
toxicity
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
03 May 2021
03 May 2021
Historique:
received:
12
03
2021
revised:
29
04
2021
accepted:
30
04
2021
entrez:
2
6
2021
pubmed:
3
6
2021
medline:
3
6
2021
Statut:
epublish
Résumé
The response to immunotherapy has been little investigated in overweight and obese cancer patients. We evaluated the relationships between BMI, toxicity, and survival in patients treated by immunotherapy for metastatic cancer. We included metastatic cancer patients treated by immunotherapy between January 2017 and June 2020 at the Centre Léon Bérard. In total, 272 patients were included: 64% men and 36% women, with a median age of 61.4 years. BMI ≥ 25 in 34.2% and 50% had non-small cell lung cancer (
Identifiants
pubmed: 34063692
pii: cancers13092200
doi: 10.3390/cancers13092200
pmc: PMC8124396
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
J Clin Invest. 2017 Jan 3;127(1):1-4
pubmed: 28045402
Sci Rep. 2019 Feb 21;9(1):2447
pubmed: 30792455
J Cancer Res Clin Oncol. 2015 Jul;141(7):1237-47
pubmed: 25537963
Oncoimmunology. 2019 Mar 6;8(5):e1580128
pubmed: 31069139
Nat Med. 2019 Jan;25(1):141-151
pubmed: 30420753
Immunotherapy. 2015;7(4):319-22
pubmed: 25917623
Cancer. 2020 Feb 1;126(3):575-582
pubmed: 31648379
Oncoimmunology. 2020 Apr 16;9(1):1751548
pubmed: 32363123
Nature. 2006 Dec 14;444(7121):860-7
pubmed: 17167474
Oncotarget. 2017 May 2;8(18):30606-30616
pubmed: 28389628
Cancer Epidemiol. 2016 Apr;41:8-15
pubmed: 26775081
Cell. 2020 Dec 23;183(7):1848-1866.e26
pubmed: 33301708
Nat Med. 1995 Sep;1(9):950-3
pubmed: 7585223
Br J Cancer. 2017 Jun 27;117(1):148-155
pubmed: 28588319
Cancer Immunol Immunother. 2021 Jan;70(1):89-100
pubmed: 32648164
J Immunother. 2020 Jan;43(1):1-7
pubmed: 31574022
Int Immunopharmacol. 2019 Sep;74:105745
pubmed: 31302449
Eur J Cancer. 2020 Jan;124:170-177
pubmed: 31794927
J Cachexia Sarcopenia Muscle. 2020 Apr;11(2):366-380
pubmed: 31916411
Br J Cancer. 2017 Jan;116(3):310-317
pubmed: 28072766
Appl Physiol Nutr Metab. 2008 Oct;33(5):997-1006
pubmed: 18923576
J Immunother Cancer. 2019 Feb 27;7(1):57
pubmed: 30813970
Sci Rep. 2019 Oct 1;9(1):14039
pubmed: 31575933
J Immunother Cancer. 2019 Mar 29;7(1):89
pubmed: 30922394
Circulation. 2011 Nov 1;124(18):1996-2019
pubmed: 21947291
J Clin Oncol. 2016 Dec 10;34(35):4270-4276
pubmed: 27903155
PLoS One. 2018 Oct 1;13(10):e0204729
pubmed: 30273398
J Clin Oncol. 2016 Oct 20;34(30):3655-3663
pubmed: 27601543
J Hepatol. 2015 Jul;63(1):131-40
pubmed: 25724366
Diabetes Care. 2012 Nov;35(11):2402-11
pubmed: 23093685
Invest New Drugs. 2017 Aug;35(4):436-441
pubmed: 28396974
N Engl J Med. 2012 Jun 28;366(26):2443-54
pubmed: 22658127
BMJ. 2018 Mar 14;360:k793
pubmed: 29540345
Int J Mol Sci. 2020 Oct 21;21(20):
pubmed: 33096896
Curr Oncol Rep. 2016 Oct;18(10):62
pubmed: 27541923
Elife. 2020 Nov 10;9:
pubmed: 33170123
World Health Organ Tech Rep Ser. 1995;854:1-452
pubmed: 8594834
J Immunother. 2012 Feb-Mar;35(2):169-78
pubmed: 22306905
Cancer Res. 2018 Apr 15;78(8):1906-1912
pubmed: 29654153
Annu Rev Pathol. 2016 May 23;11:421-49
pubmed: 27193454
Diabetes Res Clin Pract. 2018 Sep;143:310-319
pubmed: 30086371
Int J Obes. 1983;7(2):99-107
pubmed: 6862762
Int J Chronic Dis. 2020 Apr 23;2020:4928648
pubmed: 32373643
N Engl J Med. 2016 Aug 25;375(8):794-8
pubmed: 27557308
BMC Med. 2015 Sep 04;13:211
pubmed: 26337719
J Clin Oncol. 2017 Dec 1;35(34):3807-3814
pubmed: 28841387
J Immunother Cancer. 2020 Oct;8(2):
pubmed: 33077515
N Engl J Med. 2019 Oct 17;381(16):1535-1546
pubmed: 31562797
Proc Nutr Soc. 2018 Nov;77(4):388-393
pubmed: 30001763
Bull Cancer. 2016 Nov;103(11):949-950
pubmed: 27816168
Autoimmun Rev. 2014 Sep;13(9):981-1000
pubmed: 25092612
JAMA Oncol. 2020 Apr 1;6(4):512-518
pubmed: 31876896
Nat Rev Endocrinol. 2019 May;15(5):288-298
pubmed: 30814686
Ann Intern Med. 2015 Dec 1;163(11):880-1
pubmed: 26551376
N Engl J Med. 2010 Dec 2;363(23):2211-9
pubmed: 21121834
Ann Oncol. 2018 Feb 1;29(suppl_2):ii1-ii9
pubmed: 29506228
J Clin Endocrinol Metab. 2020 Oct 1;105(10):
pubmed: 32668461
J Clin Invest. 2005 May;115(5):1111-9
pubmed: 15864338
J Thorac Dis. 2020 Oct;12(10):5718-5728
pubmed: 33209404
Lancet Oncol. 2018 Mar;19(3):310-322
pubmed: 29449192
Clin Pharmacokinet. 2000 Sep;39(3):215-31
pubmed: 11020136
Sci Rep. 2020 Jan 29;10(1):1456
pubmed: 31996766
Mol Cell Endocrinol. 2010 Mar 25;316(2):129-39
pubmed: 19723556
Perioper Med (Lond). 2016 Oct 26;5:30
pubmed: 27800156
Lancet. 2019 May 4;393(10183):1819-1830
pubmed: 30955977
Am J Clin Oncol. 2021 Feb 1;44(2):74-81
pubmed: 33350681
Lung Cancer. 2020 Jan;139:140-145
pubmed: 31786476
J Transl Med. 2020 Jun 12;18(1):235
pubmed: 32532255
JAMA Oncol. 2018 Mar 1;4(3):374-378
pubmed: 28975219
Nature. 1998 Aug 27;394(6696):897-901
pubmed: 9732873
Eur J Cancer. 2020 Mar;128:17-26
pubmed: 32109847